2. Academic Validation
  3. Targeting human CD2 by the monoclonal antibody CB.219 reduces intestinal inflammation in a humanized transfer colitis model

Targeting human CD2 by the monoclonal antibody CB.219 reduces intestinal inflammation in a humanized transfer colitis model

  • Clin Immunol. 2015 Mar;157(1):16-25. doi: 10.1016/j.clim.2015.01.004.
Ulrike Erben 1,  Nina N Pawlowski 1,  Katja Doerfel 1,  Christoph Loddenkemper 2,  Jörg C Hoffmann 3,  Britta Siegmund 1,  Anja A Kühl 4
Affiliations

Affiliations

  • 1 Department of Medicine I-Gastroenterology, Infectious Diseases and Rheumatology and Research Center ImmunoSciences, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin D-12203, Germany.
  • 2 Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin D-12203, Germany.
  • 3 Department of Medicine I, St. Marienkrankenhaus, Salzburger Straße 15, Ludwigshafen D-67067, Germany.
  • 4 Department of Medicine I-Gastroenterology, Infectious Diseases and Rheumatology and Research Center ImmunoSciences, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin D-12203, Germany. Electronic address: anja.kuehl@charite.de.
PMID: 25596454 DOI: 10.1016/j.clim.2015.01.004
Abstract

The cell adhesion molecule CD2 facilitates antigen-independent T-cell activation and CD2 deficiency or blockade reduces intestinal inflammation in murine models. We here aimed to evaluate the therapeutic potential of monoclonal antibodies (mAb) specific for human CD2 in colitis treatment. Transfer colitis induced by naïve CD4(+) T cells expressing human CD2 was treated with anti-human CD2 mAb. The mAb CB.219 protected from severe colitis in a preventive treatment regimen, while therapeutic treatment ameliorated intestinal inflammation. Diminished intestinal tissue damage was paralleled by a profound suppression of lamina propria lymphocytes to produce pro-inflammatory cytokines and tumor necrosis factor α as well as the neutrophil chemoattractant CXC motif ligand 1 and the CC chemokine ligand 3. Furthermore, infiltration with macrophages and T cells was low. Thus, reduced intestinal inflammation in our humanized colitis model by targeting CD2 on T cells with the mAb CB.219 suggests a novel approach for colitis treatment.

Keywords

Human CD2; IBD mouse model; Monoclonal antibody CB.219; Reduced intestinal inflammation; Transfer colitis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z